Search our Database of Scientific Publications and Authors

I’m looking for a

    3451 results match your criteria Plaque Psoriasis

    1 OF 70

    Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial.
    Br J Dermatol 2017 Aug 17. Epub 2017 Aug 17.
    Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.
    Background: Indigo naturalis and its refined formulation, Lindioil, are effective in treating psoriatic symptoms topically. Indirubin is the active ingredient in indigo naturalis.

    Objectives: To determine the efficacy and safety of different concentrations of indirubin in Lindioil ointment for treating psoriasis. Read More

    Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry.
    Dermatol Ther (Heidelb) 2017 Aug 16. Epub 2017 Aug 16.
    AbbVie Inc, North Chicago, IL, USA.
    Introduction: ESPRIT (NCT00799877) is an ongoing 10-year international prospective observational registry evaluating the long-term safety and effectiveness of originator adalimumab in routine clinical practice for adult patients with chronic plaque psoriasis. Herein, we report the long-term safety, effectiveness, and patient-reported outcomes (PROs) following adalimumab treatment over the first 7 years of the ESPRIT registry.

    Methods: All treatment-emergent (All-TE) adverse events (AE) since the initial (first ever) dose of adalimumab were assessed. Read More

    Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    J Drugs Dermatol 2017 Aug;16(8):801-808

    INTRODUCTION: Many options are available for patients with moderate to severe plaque psoriasis. Patients with moderate disease, however, are often undertreated and do not achieve satisfactory clearance. UNVEIL (NCT02425826) assessed efficacy and safety of apremilast in patients with chronic moderate plaque psoriasis. Read More


    Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide.
    J Drugs Dermatol 2017 Aug;16(8):779-790

    Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected. The current goal of treatment in psoriasis is to improve the signs and symptoms of disease, whilst minimizing the burden of disease on patient health-related quality of life. Psoriasis can also be associated with other comorbidities such as joint disease, cardiovascular disease, and depression, which can add to the complexity of treatment. Read More


    A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
    J Drugs Dermatol 2017 Aug;16(8):747-752

    BACKGROUND: Topical corticosteroids are known to impair the epidermal barrier, even after short-term use, whereas topical vitamin D analogues can have a reparative effect. Combination products using corticosteroids and vitamin D analogues have gained popularity in recent years and may provide a means to minimize skin atrophy in patients treated with topical corticosteroids.

    OBJECTIVE: To compare epidermal barrier function and cutaneous atrophy after 4 weeks of calcipotriene 0. Read More


    Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.
    J Drugs Dermatol 2017 Aug;16(8):734-741

    BACKGROUND: An issue in long-term clinical trials of biologics in psoriasis is how to handle missing efficacy data. This methodological challenge may not be understood by clinicians, yet can have a significant effect on the interpretation of clinical trials.

    OBJECTIVE Evaluate the effects of different data imputation methods on apparent secukinumab response rates. Read More


    Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy.
    Dermatol Ther (Heidelb) 2017 Aug 7. Epub 2017 Aug 7.
    Department of Dermatology, Bichat-Claude Bernard Hospital, Paris 7 Denis Diderot University, Paris, France.
    Fixed-dose combination topical therapy with corticosteroid and vitamin D analog provides effective treatment and possible long-term management of psoriasis. The anti-inflammatory and immunomodulatory effects of corticosteroids and vitamin D analogs in treating psoriasis are well investigated; their complementary effects lead to the disruption of the inflammatory feedback loop underlying psoriasis pathogenesis. Recent preclinical data showed that combination therapy is more effective than monotherapies of the active ingredients in preventing activation of resting pro-inflammatory cells, inducing immunomodulation, reducing inflammatory responses by regulating T cell production, and normalizing keratinocytes. Read More

    Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.
    Front Pharmacol 2017 12;8:460. Epub 2017 Jul 12.
    State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau, China.
    Although initially described as an anti-tumor mediator, tumor necrosis factor-alpha (TNF) is generally considered as the master pro-inflammatory cytokine. It plays a crucial role in the pathogenesis of inflammatory diseases, such as rheumatoid arthritis (RA), inflammatory bowel disease, ankylosing spondylitis (AS), and psoriasis. Consequently, anti-TNF therapy has become mainstay treatment for autoimmune diseases. Read More

    Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.
    J Dermatolog Treat 2017 Aug 8:1-25. Epub 2017 Aug 8.
    f Novartis Pharmaceuticals , Barcelona , Spain.
    Objective: To compare the cost-consequence of biologic drugs for moderate-severe psoriasis from the perspective of the Spanish National Health System.

    Methods: We built a decision tree with a 2-year time horizon. Efficacy data for biologics (etanercept, infliximab, adalimumab, ustekinumab and secukinumab) was drawn from published meta-analyses: PASI75 for the induction phase and PASI90 for the rest of follow-up. Read More

    Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study.
    J Dermatolog Treat 2017 Aug 18:1-3. Epub 2017 Aug 18.
    b Department of Clinical and Experimental Medicine, Section of Dermatology , University of Messina , Messina , Italy.
    Background: Etanercept is licensed for the treatment of moderate-to-severe plaque psoriasis in children.

    Objectives: The aim of this analysis was to investigate effectiveness, tolerability, and reasons for discontinuation of etanercept in a real-life cohort of children and adolescents with moderate to severe plaque psoriasis.

    Methods: Data collected from a number of centers belonging to the 'Pediatric Dermatology Group' of the Italian Society of Dermatology (SIDeMaST) were examined in patients (age ≤17 years) who started treatment with etanercept from 2011 to 2015. Read More

    [Amoxicillin-induced skin rash sparing a plaque of erythema migrans: Renbök phenomenon: Case report and literature review].
    Ann Dermatol Venereol 2017 Aug 2. Epub 2017 Aug 2.
    Service de dermatologie, centre hospitalier René-Dubos, 6, avenue de l'île-de-France, 95300 Pontoise, France.
    Introduction: Renbök phenomenon describes the inhibition of a lesion when a different one appears. We describe the first case of Renbök phenomenon occurring in a context of erythema migrans (EM) spared by an amoxicillin-induced skin rash and we also present a literature review.

    Case Report: A 60-year-old patient was treated with amoxicillin for EM on the right knee and subsequently developed generalized erythema as a result of an antibiotic-induced skin rash, with sparing of the area previously affected by EM. Read More

    A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis.
    Indian Dermatol Online J 2017 Jul-Aug;8(4):246-249
    Department of Dermatology, ESI Hospital, Okla, New Delhi, India.
    Background: While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse.

    Aims: The current study assessed the effectiveness of itolizumab in real-world settings.

    Materials And Methods: This study assessed psoriasis area severity index (PASI), dermatology quality of life index (DLQI), safety, and tolerability data from a registry of itolizumab maintained by Syngene International, Bangalore. Read More

    Topical Therapies in Psoriasis.
    Indian Dermatol Online J 2017 Jul-Aug;8(4):235-245
    Dr. D.Y. Patil Medical College and Research Center, Navi Mumbai, Maharashtra, India.
    Topical therapy as monotherapy is useful in psoriasis patients with mild disease. Topical agents are also used as adjuvant for moderate-to-severe disease who are being concurrently treated with either ultraviolet light or systemic medications. Emollients are useful adjuncts to the treatment of psoriasis. Read More

    The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE).
    Ann Dermatol 2017 Aug 21;29(4):462-470. Epub 2017 Jun 21.
    Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
    Background: Psoriasis is an immune-mediated, chronic inflammatory disease affecting multiple aspects of patients' lives. Its epidemiology varies regionally; however, nationwide epidemiologic data on psoriasis depicting profile of Korean patients has not been available to date.

    Objective: To understand nationwide epidemiologic characteristics and clinical features of adult patients with psoriasis visited university hospitals in Korea. Read More

    Gene Expression Analysis of Inflammatory Cytokines in Korean Psoriatic Patients.
    Ann Dermatol 2017 Aug 21;29(4):422-426. Epub 2017 Jun 21.
    Department of Dermatology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.
    Background: Although phenotypic heterogeneity of psoriasis is suggested by the alternate activation of either T-helper (Th)1-related or Th17-related cytokines, little is known about the mRNA levels of inflammatory cytokines.

    Objective: To investigate whether there is differential expression of Th1-related and Th17-related inflammatory cytokine genes 1) between psoriatic patients and healthy controls, and 2) between patients with different psoriasis phenotypes.

    Methods: Twenty-five patients with psoriasis (10 with guttate psoriasis and 15 with plaque psoriasis) and 5 healthy volunteers were enrolled in this study. Read More

    Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    J Med Econ 2017 Aug 1:1-27. Epub 2017 Aug 1.
    e Central Dermatology , St. Louis , MO , USA.
    Background: Evidence of the cost-efficacy of ixekizumab for the treatment of moderate-to-severe plaque psoriasis (PsO) in the United States (US) is limited.

    Objective: To estimate the number needed to treat (NNT) and monthly cost of achieving one additional Psoriasis Area and Severity Index (PASI) 75, 90, and 100 responder for ixekizumab and other Food and Drug Administration (FDA)-approved biologics in PsO.

    Methods: A network meta-analysis estimated the probability of achieving PASI 75, 90, or 100 response during induction for each biologic. Read More

    Tissue hemostasis is shifted toward thrombogenesis in the psoriatic plaques.
    Pathol Res Pract 2017 Jul 15. Epub 2017 Jul 15.
    Department of Histology in Zabrze, School of Medicine with the Division of Dentistry, Medical University of Silesia in Katowice, Poland. Electronic address:
    Background: Psoriasis is a common autoimmune disease of unknown etiology. Recently, much attention has been paid to evidence that a local hypercoagulable state is an important contributing factor to the development of inflammatory skin diseases. Thus, the aim of this study was to characterize the local hemostasis in the affected skin of patients with psoriasis. Read More

    Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.
    Br J Dermatol 2017 Jul 28. Epub 2017 Jul 28.
    University of Connecticut Health Center and Probity Medical Research, Farmington, CT, USA.
    Background: ABP 501, an FDA- and EMA-approved biosimilar, is highly similar to adalimumab in structure, function, and pharmacokinetics.

    Objective: Demonstrate similarity in efficacy, safety, and immunogenicity of ABP 501 versus adalimumab for moderate-to-severe plaque psoriasis.

    Methods: Patients were randomised (1:1) to receive ABP 501 or adalimumab 40 mg every 2 weeks for 16 weeks. Read More

    Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.
    Clin Drug Investig 2017 Jul 28. Epub 2017 Jul 28.
    Department of Dermatology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301, Middle Yanchang Road, Jing'an District, Shanghai, 200072, China.
    Psoriasis is a common, chronic inflammatory skin disease and cannot be cured. The treatment of moderate-to-severe plaque psoriasis has been revolutionized with the development of biologic agents for nearly 20 years. Current studies show that interleukin-23 and interleukin-17 play remarkable roles in the pathogenesis of psoriasis. Read More

    Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides.
    Clin Rev Allergy Immunol 2017 Jul 27. Epub 2017 Jul 27.
    Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
    Extra-articular manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and various spondyloarthritides including psoriatic arthritis, ankylosing spondylitis, reactive arthritis, and inflammatory bowel disease-associated spondyloarthritis often involve the skin and may occur before or after diagnosis of these rheumatic diseases. Cutaneous manifestations encompass a wide range of reactions that may have a notable negative impact not only on the physical but especially on the emotional and psychosocial well-being of these patients. Several cutaneous manifestations have been related to rheumatoid arthritis such as subcutaneous nodules including classical rheumatoid nodules, accelerated rheumatoid nodulosis, and rheumatoid nodulosis; vascular disorders like rheumatoid vasculitis, livedo racemosa, and Raynaud's phenomenon; and neutrophilic and/or granulomatous diseases like pyoderma gangrenosum, Sweet's syndrome, rheumatoid neutrophilic dermatitis, interstitial granulomatous dermatitis with arthritis, as well as palisaded neutrophilic and granulomatous dermatitis. Read More

    Influence of narrowband ultraviolet B phototherapy on serum tumour necrosis factor-like weak inducer of apoptosis (TWEAK) in patients with psoriasis.
    Clin Exp Dermatol 2017 Jul 27. Epub 2017 Jul 27.
    Department of Dermatology and Venereology, Medical University of Bialystok, Bialystok, Poland.
    Psoriasis is characterized by keratinocyte resistance to apoptosis. We recently demonstrated an increase in serum tumour necrosis factor-like weak inducer of apoptosis (TWEAK) in patients after topical treatment for psoriasis. We decided to verify whether narrowband ultraviolet B (NB-UVB) has a similar effect. Read More

    Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
    Drug Des Devel Ther 2017 7;11:2065-2075. Epub 2017 Jul 7.
    Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
    Brodalumab is a novel fully human immunoglobulin G2 monoclonal antibody that antagonizes the interleukin (IL)-17 pathway by binding with high affinity to human IL-17RA. The role of IL-17A in the pathogenesis of psoriasis, as well as the remarkable effectiveness of IL-17 inhibitors in the treatment of moderate-to-severe plaque psoriasis, is well established. The mechanism of action of brodalumab is unique in that it inhibits the IL-17 receptor compared to the two other currently FDA-approved IL-17 inhibitors, secukinumab and ixekizumab, which inhibit the IL-17A molecule itself. Read More

    Psoriasis: a mixed autoimmune and autoinflammatory disease.
    Curr Opin Immunol 2017 Jul 21;49:1-8. Epub 2017 Jul 21.
    Department of Dermatology, University of Michigan, 1910 Taubman Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. Electronic address:
    In recent years marked progress has been made in our understanding of the critical biologic and immunologic pathways involved in psoriasis. Genetic studies have demonstrated that susceptibility to psoriasis involves components of both the adaptive and innate immune system and not surprisingly activation of both of these arms of the immune system is found in psoriatic skin. While adaptive immune responses predominate in chronic plaque psoriasis, innate and autoinflammatory responses dominate in pustular forms of psoriasis, with other clinical subtypes extending on a spectrum between plaque and pustular psoriasis. Read More

    Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial.
    PLoS One 2017 19;12(7):e0180762. Epub 2017 Jul 19.
    Kineta Inc., Seattle, WA, United States of America.
    Background: Dalazatide is a specific inhibitor of the Kv1.3 potassium channel. The expression and function of Kv1. Read More

    Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
    J Dermatol 2017 Jul 17. Epub 2017 Jul 17.
    Probity Medical Research and K. Papp Clinical Research Inc., Waterloo, Ontario, Canada.
    Tofacitinib is an oral Janus kinase inhibitor. These post-hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52-week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b. Read More

    Serum levels of tumor necrosis factor-alpha in patients with psoriasis before, during and after narrow-band UVB phototherapy.
    G Ital Dermatol Venereol 2017 Jul 11. Epub 2017 Jul 11.
    Department of Dermatology, Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
    Background/purpose: Narrow-band UVB (NB-UVB) phototherapy is widely used worldwide for moderate and severe psoriasis, which is a chronic autoimmune inflammatory disease characterized by skin infiltrates of Th1-, Th17- and Th22-cells releasing locally pro- inflammatory cytokines. We investigate serum levels of tumor necrosis factor-α (TNF-α) in psoriatic patients before and after NB-UVB phototherapy.

    Methods: Twenty-eight subjects with moderate/severe plaque type psoriasis were enrolled. Read More

    The metabolic analysis of psoriasis identifies the associated metabolites while providing computational models for the monitoring of the disease.
    Arch Dermatol Res 2017 Jul 10. Epub 2017 Jul 10.
    Department of Biochemistry, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, 50411, Tartu, Estonia.
    The majority of studies on psoriasis have focused on explaining the genetic background and its associations with the immune system's response. The aim of this study was to identify the low-molecular weight compounds contributing to the metabolomic profile of psoriasis and to provide computational models that help with the classification and monitoring of the severity of the disease. We compared the results from targeted and untargeted analyses of patients' serums with plaque psoriasis to controls. Read More

    Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment.
    Ther Drug Monit 2017 Aug;39(4):333-338
    Departments of *Hospital Pharmacy, †Dermatology, and ‡Immunology, Erasmus MC, Rotterdam, the Netherlands; §Department of R&D, Sanquin Reagents, Amsterdam, the Netherlands; ¶Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam, the Netherlands; and ‖Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands.
    Aim: Etanercept has shown to mediate a favorable effect on immune-mediated inflammatory diseases (IMID), including plaque psoriasis. Therapeutic drug monitoring (TDM) of etanercept could improve clinical outcome and cost-effectiveness. A high intrapatient variability (IPV) of etanercept trough concentrations at standard dosing would reduce the feasibility of therapeutic drug monitoring. Read More

    Eruptive Seborrheic Keratoses Restricted to Plaque/Patch-Stage Mycosis Fungoides.
    Case Rep Dermatol 2017 May-Aug;9(2):35-39. Epub 2017 Jun 8.
    Department of Dermatology, CHU Sart Tilman, University of Liège, Liège, Belgium.
    Eruptive seborrheic keratoses (ESK) are rare in dermatology. They are usually inflammatory in nature and may be encountered as Leser-Trélat sign. ESK may also be simultaneously observed with hepatic angiomas, chemotherapy, segmental neurofibromatosis, HIV or erythrodermic pityriasis rubra pilaris, psoriasis, and drug eruption. Read More

    Narrowband UVB treatment increases serum 25-hydroxyvitamin D levels in patients with chronic plaque psoriasis.
    Cutis 2017 Jun;99(6):431-435
    Department of Dermatology and Venereology, Eskişehir Osmangazi University, Turkey.
    The aim of this study was to investigate the effects of narrowband UVB (NB-UVB) phototherapy on serum 25-hydroxyvitamin D (25[OH]D) levels and related parameters in patients with psoriasis. Forty-nine participants with moderate to severe plaque-type psoriasis were included in this study and were treated with NB-UVB therapy 3 times weekly for 6 months or until psoriasis area and severity index (PASI) 75 was achieved. Participants' serum 25(OH)D, calcium, phosphorus, parathyroid hormone (PTH), and alkaline phosphatase (ALP) levels were measured at baseline and completion of treatment, along with PASI scores. Read More

    Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient.
    Drug Saf Case Rep 2017 Dec;4(1)
    School of Medicine, University of South Carolina, 6311 Garners Ferry Road, Building #3, Columbia, SC, 29209, USA.
    A 62-year-old white woman with a history of hepatitis C and type 2 diabetes mellitus developed urticaria during treatment with ustekinumab for plaque psoriasis. The patient received two 45-mg ustekinumab injections in her first 2 months and then one 45-mg injection every 3 months for her psoriasis. After 10 months, she developed a round red rash on her skin diffusely on her body. Read More

    Monocyte subpopulations study in patients with plaque psoriasis.
    Med Hypotheses 2017 Jul 29;104:101-103. Epub 2017 May 29.
    Immunology Service, Prof. Edgard Santos University Hospital, Federal University of Bahia, Brazil; Gonçalo Moniz Institute, Fiocruz, Salvador, BA, Brazil.
    Psoriasis is a chronic and systemic, immune-mediated, inflammatory disease, mainly manifested by skin and / or joints lesions, presenting with a wide degree of clinical severity, but generally with great impact on patients' quality of life. Despite advances in the understanding of its pathogenesis, especially regarding the participation of T-lymphocytes and the key role of TNF, the triggering factor of the disease at the molecular level remains unknown, as well as the function of other cell populations. By presenting antigens to T-lymphocytes, monocytes assume an important role in both innate and adaptive immune response. Read More

    Quality of life, treatment satisfaction and efficacy of non-biological systemic therapies in patients with plaque psoriasis: study protocol for a prospective observational study.
    BMJ Open 2017 Jun 30;7(6):e014279. Epub 2017 Jun 30.
    Department of Dermatology, University of Heidelberg, Heidelberg, Germany.
    Introduction: Psoriasis vulgaris often leads to a significant impaired quality of life and dissatisfaction with the existing therapeutic approaches. However, patients' quality of life and treatment satisfaction are of utmost importance, since it is positively related to therapy adherence and encourages patient's compliance. The study described herein evaluates the quality of life, treatment satisfaction and efficacy during the initial 6 months of treatment with a non-biological systemic agent in a real-life clinical setting. Read More

    Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes.
    BMJ Case Rep 2017 Jun 29;2017. Epub 2017 Jun 29.
    Havener Eye Institute, Department of Ophthalmology and Visual Science, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
    A 64-year-old man with type 2 diabetes mellitus and plaque psoriasis presented to the emergency room with 3 days of progressive right eye pain and decreased vision. After extensive workup and multidisciplinary team effort, the patient was diagnosed with and treated for unilateral endogenous methicillin-sensitive Staphylococcus aureus endophthalmitis, bacteraemia and osteomyelitis of the foot. The patient had been started on the interleukin 17 (IL-17) inhibitor secukinumab for his treatment-resistant plaque psoriasis 4 weeks prior to presentation. Read More

    Topical corticosteroids or vitamin D analogues for plaque psoriasis?
    Medwave 2017 Jun 27;17(Suppl 2):e6981. Epub 2017 Jun 27.
    Proyecto Epistemonikos, Santiago, Chile; Departamento de Dermatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
    Psoriasis is a frequent chronic inflammatory disease. The plaque variant being its most common form of presentation. Although there is still no cure, treatment alternatives that induce remission and reduce lesions are available. Read More

    Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.
    Ther Deliv 2017 Jun 29. Epub 2017 Jun 29.
    Division of Dermatology, Baylor University Medical Center, 3900 Junius Street, Suite 125, Dallas, TX 75246, USA.
    Psoriasis is a common chronic immune-mediated skin disease which has a significant impact on patients' quality of life, and is associated with numerous comorbidities (i.e., psoriatic arthritis, Crohn's disease and cardiovascular disease). Read More

    The Role of IL-23 and the IL-23/TH 17 Immune Axis in the Pathogenesis and Treatment of Psoriasis.
    J Eur Acad Dermatol Venereol 2017 Jun 27. Epub 2017 Jun 27.
    Department of Dermatology, University of Munich, Munich, Germany.
    Psoriasis is a chronic, immune-mediated disease affecting more than 100 million people worldwide and up to 2.2% of the UK population. The etiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious, and lifestyle factors. Read More

    Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
    Drug Des Devel Ther 2017 2;11:1643-1651. Epub 2017 Jun 2.
    Department of Dermatology.
    Psoriasis is a chronic inflammatory disease affecting up to 3% of the general population, associated with discomfort and impaired quality of life. In recent years, the pathogenic cytokine network of psoriasis has been extensively studied leading to the development of new treatments that provide greater efficacy. Interleukin 17A (IL-17A) has been recognized as a crucial cytokine that mediates immunopathogenesis of psoriasis. Read More

    Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Drugs Today (Barc) 2017 May;53(5):283-297
    Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
    Psoriasis is a chronic immune-mediated inflammatory skin disease in which the alteration of the interleukin-23 (IL-23)/IL-17 cytokine axis appears to be crucial from a pathogenetic perspective. This has been confirmed by the efficacy of monoclonal antibodies blocking IL-17A, such as secukinumab and ixekizumab. Brodalumab is a human anti-IL-17 receptor A (IL-17RA) monoclonal antibody that inhibits the biological activity of IL-17A, IL-17F and other IL-17 isoforms, and has been approved (210 mg s. Read More

    Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis.
    Nanomedicine 2017 Jun 22;13(7):2251-2262. Epub 2017 Jun 22.
    Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India. Electronic address:
    Thymoquinone (TMQ) is reported with good anti-psoriatic activity; however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ hinder its delivery to target site. To address these delivery challenges of TMQ, lipospheres were explored. The topical use of lipospheres offers an effective mean of penetration along with stability and scalability. Read More

    Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.
    Dermatol Ther (Heidelb) 2017 Jun 21. Epub 2017 Jun 21.
    Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
    Introduction: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway.

    Methods: We summarize the available phase III results to date, establishing the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis. Read More

    Sleep Quality and its Association with Disease Severity in Psoriasis.
    Eurasian J Med 2017 Jun;49(2):124-127
    Department of Dermatalogy, Atatürk University School of Medicine, Erzurum, Turkey.
    Objective: The main purpose of this research was to crosscheck sleep quality in patients with psoriasis with that in healthy individuals and to evaluate a possible relationship between sleep quality and disease severity in these patients.

    Materials And Methods: Fifty-eight patients with plaque psoriasis and 58 age- and gender-matched healthy individuals were included. The Psoriasis Area and Severity Index (PASI) scoring method was used to assess the disease severity in patients with psoriasis. Read More

    Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
    J Dermatol 2017 Jun 21. Epub 2017 Jun 21.
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
    The present study describes a subgroup analysis of 33 Japanese patients participating in UNCOVER-1, an international, placebo-controlled, phase 3 study of ixekizumab in patients with moderate-to-severe psoriasis. Patients were randomized to a placebo (n = 13) or ixekizumab 80 mg every 4 (IXEQ4W, n = 12) or 2 (IXEQ2W, n = 8) weeks, from week 0-12. At week 12, ixekizumab-treated patients with a static Physician Global Assessment score 0 or 1 (sPGA [0,1]; n = 16) were re-randomized to a placebo (n = 6), ixekizumab 80 mg every 12 (IXEQ12W, n = 5) or 4 (IXEQ4W, n = 5) weeks, from week 12-60. Read More

    Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial.
    Br J Dermatol 2017 Jun 21. Epub 2017 Jun 21.
    Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
    Background: Guselkumab, an anti-interleukin-23 monoclonal antibody, demonstrated significant efficacy in Phase 3 psoriasis trials.

    Objective: Evaluate the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis with an inadequate response to ustekinumab.

    Methods: In this Phase 3, randomized, double-blind study, 871 patients received open-label ustekinumab (45mg or 90mg) at weeks 0 and 4. Read More

    IL-17 for therapy.
    J Dermatol Sci 2017 Jun 15. Epub 2017 Jun 15.
    Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
    The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies supposed to treat a variety of inflammatory diseases. The forerunner Secukinumab, an IL-17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ankylosing spondylitis. Ixekizumab and Brodalumab, both also targeting the IL-17 pathway, were also recently approved by the FDA for plaque psoriasis. Read More

    1 OF 70